ESCAPE

ESCAPE-ing Stroke.

Study Progression Status Number of Sites Number of Patients Enrolled
Closed 22 316
studies-escape-escape

Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times

The purpose of the study is to understand whether a new treatment of stroke – endovascular clot removal – can be added to the current standard of care to improve patient outcomes.

All patients will receive the best standard stroke treatment. This includes treating patients with the clot dissolving drug tPA (tissue plasminogen activator). However, t-PA does not work in some patients and others are not eligible to receive t-PA because they present too late for treatment (they woke up with their stroke symptoms or their stroke was not witnessed).

During endovascular revascularization the blockage in the artery is removed with the use of devices called stentreivers and or by giving clot dissolving drug at the site of the blockage in the artery to restore blood flow. Stentrievers are devices that have been designed by different companies to remove blood clots from arteries.

Key factors for success are very rapid treatment, careful patient selection with neurovascular imaging and complete early reperfusion. Up to 40% of the patients are expected to have atrial fibrillation as the underlying cause of their stroke.

Approximately 400 subects at 25 hospitals across Canada, USA, Europe and Asia will participate in this study. The study is 50% recruited.

ESCAPE – ClinicalTrials.gov

Investigators:

MIchael D Hill, MD MSc FRCPC University of Calgary
Andrew M Demchuk, MD FRCPC University of Calgary
Mayank Goyal, MD FRCPC University of Calgary

Countries Participating:

  • Canada
  • United States
  • Europe
  • United Kingdom
  • South Korea